Latest News and Press Releases

Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has been added to ...

Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ...

Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The psoriasis market is undergoing significant...

Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The tumor necrosis...

Vancouver, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Global Biosimilar Market Poised for Rapid Growth with 17.9% CAGR, Fueled by Rising Cancer Cases and Regulatory Approvals In 2032, the global biosimilar...

Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ...

Dublin, Aug. 10, 2022 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Infliximab Market 2022-2031" report has been added to ResearchAndMarkets.com's offering. According to this market...

Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "TNF Alpha Inhibitors Global Market Report 2022: By Drug, By Route, By Disease" report has been added to ResearchAndMarkets.com's offering. The global...

Dublin, July 29, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Infliximab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Infliximab is a human-mouse...

China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China.Sorrento holds commercialization rights outside of China and intends to meet...